Anavex Life Sciences Corp (AVXL)

[williamssc]

An approval for a relatively inexpensive AD oral therapy that requires no expensive infrastructure (imaging machines, IV centers, frequent appointments) would be a massive win for the EU.

I think this is where the rubber meets the road in our MAA decision. AD is an expensive unmet public need that's looking for a better solution than current IV treatments due to costs and the logistical nightmare folks would endure. Inexpensive safe oral delivery is a no-brainer.